Clinical Trials Logo

Clinical Trial Summary

Oncological diseases are the main cause of death in developed countries and also in Uruguay. Advances in therapeutics have made possible to aspire to cure and in other cases long-term remission with a significant increase in survival and the transformation of cancer into a chronic disease. Chemotherapy treatments have some side effects and cardiotoxicity is well known within them. Heart failure (HF) is a progressive pathology, with high mortality and high resource requirements of the health system with a prognosis that may be worse than some types of cancers. The treatment of established systolic dysfunction and symptomatic HF is mainly based on the indication of inhibitors of the angiotensin-converting enzyme and beta-blockers among other pharmaceutical and no pharmaceutical interventions. Aerobic physical exercise, as a therapeutic intervention, reverses the physiopathological changes that are presumed to lead to HF in sedentary people and it is known, it is feasible to execute an exercise program in cancer patients. However, effective treatments for the primary prevention of systolic dysfunction are not well known. Our hypothesis is that an aerobic physical exercise program for at least 3 months, in subjects with lymphoma and new-onset chemotherapy, is effective in preventing left ventricular systolic dysfunction, at the end of chemotherapy and at one year. For this, the investigators propose a randomized, controlled, clinical study which is blind both for the patient and the evaluating physician, comparing the difference of global longitudinal strain (an echocardiographic result of myocardial function) pre-chemotherapy minus end of chemotherapy and minus one year after, between the active group (aerobic program) and the control group (flexibility program).


Clinical Trial Description

Hypothesis: an aerobic physical exercise program for at least 3 months, in subjects with hemato-oncological diseases that initiate chemotherapy, is effective in preventing systolic dysfunction of the left ventricle at the end of chemotherapy and one year. It is a double-blind, randomized controlled trial. Blinded for the subject, evaluating echocardiographic, and treating hematologist. Blocked randomization method stratified by sex: the randomization sequence will be software generated and centralized by an investigator independent from assistant physicians and echocardiographic evaluator. To calculate N sample the investigators took a 15% variation of longitudinal left ventricular strain ( clinically significant criteria). The mean and standard deviation of the healthy Uruguayan population was taken from an own study (19.6 ± 1.7%); considering alpha error 0.05 and power 80%, a sample of 16 in each group is required to find significant results. An additional 20% was added for possible "drop outs" resulting in a sample size of 19 subjects/group (N total 38). The intervention is a 3 months aerobic exercise program compared with a 3 months flexibility exercise program. The main outcome is the myocardial longitudinal strain variation. Secondary outcomes are related to systolic and diastolic cardiac function, quality of life, cardiac and oncological outcomes, and evaluation of adherence. Statistical analysis: Qualitative variables will be expressed in absolute and relative frequency. Continuous variables will be resumed as mean and standard deviation or median and interquartile interval regarding normal distribution. Parametric or non- parametric tests of the association will be used regarding test of normality of each continuous outcome and Chi-squared test for the association of qualitative variables. Survival analysis will be made with Kaplan Meier curves and long rank test. The project is registered in Uruguayan interventional trial registration (Ministery of Public Health) with the number 812559. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04476576
Study type Interventional
Source Universidad de la Republica
Contact Lucia Florio, MD MSc
Phone +59899606694
Email lu.floriol@gmail.com
Status Recruiting
Phase N/A
Start date March 2, 2021
Completion date March 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05271162 - Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines Phase 3
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Recruiting NCT04092309 - Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation N/A
Recruiting NCT04790266 - Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Enrolling by invitation NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Not yet recruiting NCT05040867 - Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients N/A
Recruiting NCT05851053 - Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04877899 - Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Recruiting NCT05096338 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Recruiting NCT05078190 - Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
Recruiting NCT04632407 - Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study? N/A
Completed NCT00543062 - Staccato Prochlorperazine Thorough QT/QTc Phase 1
Recruiting NCT05159479 - Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
Not yet recruiting NCT06005259 - Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX) Phase 4
Recruiting NCT05406635 - Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer N/A
Recruiting NCT04047901 - Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment N/A
Terminated NCT03038997 - Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
Completed NCT01246778 - Sunitinib and Atrial Trabeculae Contractility N/A